Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Last Close
271.55
Oct 27 • 3:59 PM ET Dollar change-2.05 Percentage change(-0.75%)
Aftermarket Close
276.20
Aftermarket • 6:33 PM ET Dollar change+4.65 Percentage change(1.71%)
Today, 1:38 PMIQVIA beats Q3 guidance with revenue $4.428B, EPS $3.34, raises 2026 outlook on strong clinical bookings and AI demand
Index
S&P 500
Market Cap
44.70B
Enterprise Value
58.99B
Income
1.38B
Sales
16.99B
Book/sh
37.49
Cash/sh
12.64
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
0.00%
Employees
93000
IPO
May 09, 2013
P/E
33.68
Forward P/E
18.90
PEG
1.80
P/S
2.63
P/B
7.24
P/C
21.49
P/FCF
20.47
EV/EBITDA
16.64
EV/Sales
3.47
Quick Ratio
0.71
Current Ratio
0.71
Debt/Eq
2.63
LT Debt/Eq
2.26
Option/Short
Yes / Yes
EPS (ttm)
8.06
EPS next Y
14.37
EPS next Q
3.63
EPS this Y
8.56%
EPS next Y
11.02%
EPS next 5Y
10.50%
EPS past 3/5Y
11.05% 40.52%
Sales past 3/5Y
4.18% 7.50%
EPS Y/Y TTM
16.68%
Sales Y/Y TTM
8.22%
EPS Q/Q
-0.36%
Sales Q/Q
8.84%
Insider Own
1.00%
Insider Trans
-6.89%
Inst Own
102.23%
Inst Trans
-1.29%
ROA
4.70%
ROE
23.01%
ROIC
6.83%
Gross Margin
26.02%
Oper. Margin
13.90%
Profit Margin
8.09%
SMA20
1.96%
SMA50
2.64%
SMA200
29.91%
Trades
Shs Outstand
164.60M
Shs Float
162.96M
52W High
282.98 -4.04%
52W Low
154.50 75.76%
Volatility
3.51% 3.02%
ATR (14)
8.70
RSI (14)
55.15
Beta
1.17
Rel Volume
1.41
Avg Volume
1.48M
Volume
2,097,244
Perf Week
1.38%
Perf Month
0.21%
Perf Quarter
9.69%
Perf Half Y
70.81%
Perf YTD
20.47%
Perf Year
24.89%
Perf 3Y
50.91%
Perf 5Y
6.79%
Perf 10Y
276.63%
Prev Close
273.60
Price
271.55
Change %
-0.75%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Berkshire James G.See RemarksSep 02 '26Option Exercise131.825,381709,32313,558Sep 04 05:00 PM
Berkshire James G.See RemarksSep 02 '26Sale261.332,668697,22810,890Sep 04 05:00 PM
JAMES G BERKSHIREOfficerSep 02 '26Proposed Sale261.322,668697,215Sep 02 04:11 PM
STAUB W RICHARDSee RemarksAug 03 '26Sale232.685,5001,279,74013,312Aug 04 05:00 PM
Patel BhavikSee RemarksJul 31 '26Sale235.271,855436,4261,348Aug 04 05:00 PM
WALTER STAUBOfficerAug 03 '26Proposed Sale232.685,5001,279,740Aug 03 04:14 PM
Sherbet EricSee RemarksJul 29 '26Sale249.165,0001,245,80020,999Jul 31 05:04 PM
Cherofsky KeriannSee RemarksJul 29 '26Sale245.21558136,8272,989Jul 31 05:03 PM
BOUSBIB ARISee RemarksJul 29 '26Option Exercise78.21156,20612,216,871992,147Jul 31 05:02 PM
BOUSBIB ARISee RemarksJul 29 '26Sale245.51106,27926,092,072885,868Jul 31 05:02 PM
BHAVIK PATELOfficerJul 31 '26Proposed Sale235.271,855436,426Jul 31 04:04 PM
KERIANN CHEROFSKYOfficerJul 29 '26Proposed Sale245.21558136,827Jul 29 04:10 PM
ERIC SHERBETOfficerJul 29 '26Proposed Sale249.165,0001,245,775Jul 29 04:07 PM
ARI BOUSBIBOfficerJul 29 '26Proposed Sale245.50106,27926,091,897Jul 29 04:04 PM
BOUSBIB ARISee RemarksDec 18 '25Option Exercise59.9050,0002,995,000857,163Dec 19 05:00 PM
BOUSBIB ARISee RemarksDec 18 '25Sale222.4336,5648,132,931820,599Dec 19 05:00 PM
ARI BOUSBIBOfficerDec 18 '25Proposed Sale222.4336,5648,132,876Dec 18 05:41 PM
Sherbet EricSee RemarksOct 29 '25Option Exercise131.8210,0001,318,20031,108Oct 31 05:01 PM
Sherbet EricSee RemarksOct 29 '25Sale219.704,000878,80027,108Oct 31 05:01 PM
BOUSBIB ARISee RemarksOct 29 '25Option Exercise59.9077,5924,647,761884,755Oct 31 05:00 PM
BOUSBIB ARISee RemarksOct 29 '25Sale220.3356,55712,461,119828,198Oct 31 05:00 PM
ARI BOUSBIBOfficerOct 29 '25Proposed Sale220.3356,55712,460,983Oct 29 04:18 PM
ERIC SHERBETOfficerOct 29 '25Proposed Sale219.704,000878,820Oct 29 04:10 PM
IQVIA Holdings, Inc. engages in the provision of analytics, technology solutions, and clinical research services to the life sciences industry. It operates through the following segments: Technology and Analytics Solutions, Research and Development Solutions, and Contract Sales and Medical Solutions. The Technology and Analytics Solutions segment supplies mission-critical information, technology solutions, and real-world evidence services to the company's life sciences clients. The Research and Development Solutions segment provides outsourced clinical research and clinical trial-related services. The Contract Sales and Medical Solutions segment offers healthcare provider and patient engagement services to both biopharmaceutical customers and the broader healthcare market. The company was founded by Dennis B. Gillings and Gary Koch in 1950 and is headquartered in Durham, NC.
CEO & ChairmanMr. Ari Bousbib
Executive VPMr. Eric M. Sherbet J.D.
President of Research & Development SolutionsMr. W. Richard Staub III
President of Commercial SolutionsMr. Alistair Grenfell
Executive VP & Chief Financial OfficerMr. Michael J. Fedock MBA